Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving long COVID symptoms, according to a ...

The phase 2 investigational new drug clinical trial tested whether a 15-day course of Paxlovid, an FDA-approved antiviral for acute COVID-19, could also help long COVID patients.

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

A novel decentralized clinical trial found that Paxlovid was ineffective in alleviating long COVID symptoms but underscored ...

Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration ...

Researchers have shown a new drug compound can prevent long COVID symptoms in mice—a landmark finding that could lead to a ...

scientists deployed every bit of cutting-edge technology available to create a bespoke drug that could target this newly emerged coronavirus. The result was a medicine called Paxlovid. But as with ...

Ritonavir has been around for decades and was originally approved to treat HIV. What are its side effects? Paxlovid seems well tolerated for now, although studies are ongoing. The drug has been in ...

Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving ... “The case study goes on to show that maybe the duration of the drug wasn’t long enough, or maybe ...

Paxlovid was granted emergency use authorisation (EUA) by the FDA in December 2021, becoming the first antiviral treatment for mild-to-moderate COVID-19 in adults who are at high risk for ...